Skip to main content
. 2017 Jan 24;20(2):137–145. doi: 10.1038/pcan.2016.69

Table 1. Non-randomised controlled trials examining the effects of continual ADT in men with prostate cancer on aBMD.

Authors N Average age (years) Change in aBMD
GnRH agonist only
6 months
  Diamond et al.45 18 78 FN−6.5% WT−7.5% Troch−6.2%
  Maillefert et al.21 12 70 LS−3.0% FN−2.7%
  Hamilton et al.44 26 71 LS−1.7% FN−1.5% Hip−1.5% 1/3Rad +9.1%
12 months
  Maillefert et al.21 12 70 LS−4.6% FN−3.9%
  Berruti et al.15 35 75 LS−2.3% FN−0.6%
  Mittan et al.22 15 75 Hip−3.3% DRad−5.3% MRad−2.7% 1/3Rad−1.6% LS−2.8% FN−2.3%
  Bergstrom et al.14 10 73 FN−3.2%
  Smith et al.25 26 65 LS−2.5% Hip−1.4%
  Lee et al.20 65 66 Hip−1.9%
  Morote et al.23 31 70 LS−4.8% FN−3.0% WT−5.6% Troch−3.6% Hip−3.8%
  Hamilton et al.44 26 71 LS−3.9% FN−3.0% Hip−2.6% 1/3Rad +9.2%
18 months
  Maillefert et al.21 12 70 LS−6.6% FN−7.1%
       
Anti-androgen only
12 months
  Smith et al.25 25 63 LS +2.5% Hip +1.1%
       
CAB
9 months
  Higano et al.19 17 69 LS−4.5% Hip−2.5%
  Galvão et al.17 69 74 Hip−1.5% LS−3.9% WB−2.4%
       
Pharmacological (any modality)
12 months
  Daniell et al.16 16 72 FN−3.4%
  Greenspan et al.18 80 69–71 Acute ADT: Hip−2.5% Troch−2.4% TRad−2.6% WB−3.3% LS−4.0% Chronic ADT: TRad−2.0%
24 months
  Daniell et al.16 16 72 FN−6.5%
  Preston et al.24 23 73 FN−1.9% Hip −1.5% Troch−2.0% LS−0.2% DRad +9.4%
       
Orchiectomy only
12 months
  Daniell et al.16 10 77 FN−2.4%
  Bergstrom et al.14 12 79 FN−4.5%
24 months
  Daniell et al.16 10 77 FN−10.0%

Abbreviations: 1/3Rad, one-third radius; aBMD, areal bone mineral density; ADT, androgen deprivation therapy; CAB, combined androgen blockade; DRad, distal radius; FN, femoral neck; GnRH, gonadotropin-releasing hormone; Hip, total hip; LS, lumbar spine; MRad, mid radius; N, number; TRad, total radius; Troch, trochanter; WB, whole body; WT, Ward’s triangle.